Bausch Health Shares Plunge 12.4% After RED-C Trial Failure Threatens XIFAXAN Revenue

The share price fell to its lowest level since November 2025 today, with an intraday decline of 1.80%.

Bausch Health’s stock has plunged 12.4% over six consecutive sessions, driven by the failure of its Phase 3 RED-C trial for a next-generation rifaximin formulation. The drug, intended to extend the lifecycle of XIFAXAN—its flagship treatment for hepatic encephalopathy—did not meet primary endpoints in delaying the first episode of the condition in cirrhosis patients. XIFAXAN accounted for 20% of Bausch’s FY2024 revenue and 85% of its Salix segment’s Q3 2025 earnings ($716 million), making the setback a critical blow to its revenue outlook. With XIFAXAN’s exclusivity set to expire by 2028, the RED-C failure removes a key growth driver, exacerbating concerns about post-2028 revenue sustainability.

The stock’s decline reflects investor anxiety over Bausch’s ability to manage its $21 billion in long-term debt and fund R&D. While XIFAXAN’s 16% year-over-year revenue growth in Q3 2025 ($2.68 billion) had bolstered cash flow, the lack of a viable replacement in its pipeline heightens risks of cash flow constraints. CEO Thomas Appio has acknowledged the setback but offered no clarity on alternative strategies, eroding market confidence. Analysts highlight the stock’s $2.43 billion market cap as undervalued relative to fair value estimates, yet recent volatility underscores the sector’s sensitivity to clinical outcomes. The company’s upcoming February 18, 2026, earnings report will be pivotal in reassessing its strategic direction amid a debt-laden and pipeline-challenged landscape.